摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

前列他林 | 54120-61-5

中文名称
前列他林
中文别名
——
英文名称
Prostalene
英文别名
——
前列他林化学式
CAS
54120-61-5
化学式
C22H36O5
mdl
——
分子量
380.5
InChiKey
GNIYHUSSKSFYBD-MFZPGRHISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    493.1±45.0 °C(Predicted)
  • 密度:
    1.094±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    27
  • 可旋转键数:
    12
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    87
  • 氢给体数:
    3
  • 氢受体数:
    5

文献信息

  • [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
    申请人:AQUESTIVE THERAPEUTICS INC
    公开号:WO2021087359A1
    公开(公告)日:2021-05-06
    Pharmaceutical compositions include a prodrug of epinephrine are described.
    药物组合物包括表述的肾上腺素前药。
  • Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
    申请人:Rogers D. Robin
    公开号:US20070093462A1
    公开(公告)日:2007-04-26
    Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.
    揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法,以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效(协同作用)以及改善易用性和制造工艺。
  • [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
    申请人:UNIV ALABAMA
    公开号:WO2010078300A1
    公开(公告)日:2010-07-08
    Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.
    本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物,以及其使用方法。进一步揭示了包括液态离子对的物质组合物,单独或溶解后使用;以及离子液体的“溶剂化”组合物,例如“水合”的组合物及其用途。
  • Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use
    申请人:Garvey S. David
    公开号:US20070032533A1
    公开(公告)日:2007-02-08
    The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.
    该发明描述了包含至少一种一氧化氮增强的血管紧张素II拮抗剂化合物或其药用盐的组合物和试剂盒,以及包含至少一种一氧化氮增强的血管紧张素II拮抗剂化合物的新型组合物,还可以包含至少一种一氧化氮增强化合物和/或至少一种治疗剂。该发明还提供了用于(a)治疗心血管疾病;(b)治疗肾血管疾病;(c)治疗糖尿病;(d)治疗由氧化应激导致的疾病;(e)治疗内皮功能障碍;(f)治疗由内皮功能障碍引起的疾病;(g)治疗肝硬化;(h)治疗子痫前症;(j)治疗骨质疏松症;(k)治疗肾病;(l)治疗外周血管疾病;(m)治疗门静脉高压症;(o)治疗中枢神经系统疾病;(p)治疗代谢综合征;和(q)治疗高脂血症的方法。一氧化氮增强的血管紧张素II拮抗剂化合物包括至少一种一氧化氮增强基团,通过碳、氧和/或氮等一个或多个位点与血管紧张素II拮抗剂化合物连接,连接方式是通过一种不能水解的键或基团。
  • Diagnostic/therapeutic agents
    申请人:Klaveness Jo
    公开号:US20050002865A1
    公开(公告)日:2005-01-06
    Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
    可定位的诊断和/或治疗活性剂,例如超声对比剂,包括悬浮在水载体液中的报告物,该报告物包含含气体或生成气体的材料,该剂能够与目标形成至少两种结合对。
查看更多